Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Sotyktu (deucravacitinib) and Otezla (apremilast) are both oral medications used to treat plaque psoriasis. However, they belong to different medication classes and have distinct characteristics. Sotyktu is a tyrosine kinase 2 (TYK2) inhibitor, while Otezla is a phosphodiesterase-4 (PDE-4) inhibitor. Sotyktu is specifically FDA-approved for moderate-to-severe plaque psoriasis, whereas Otezla is approved for plaque psoriasis, active psoriatic arthritis, and mouth sores from Behçet’s disease. Sotyktu is taken once daily, while Otezla is taken twice daily after initial dosing. Sotyktu is only available as a brand-name medication. Generic versions of Otezla have been approved, though they may not be available until 2028. Sotyktu can increase the risk of infection, including upper respiratory infection, while Otezla often causes nausea and diarrhea. Some medications, including the seziure medication carbamazepine, can make Otezla less effective. Make sure your prescriber and pharmacist have a complete list of your medications.
Sotyktu (deucravacitinib)
Otezla (apremilast)
Sotyktu (deucravacitinib)
Otezla (apremilast)
Summary of Sotyktu vs. Otezla
Summary for Tyrosine kinase 2 inhibitor
Prescription only
Sotyktu (deucravacitinib) is a medication used to treat moderate-to-severe plaque psoriasis in adults. It works as a tyrosine kinase 2 inhibitor to lessen inflammation. Sotyktu (deucravacitinib) comes as a tablet that you take once a day, with or without food. Side effects include a higher risk of infections, like upper respiratory infections. Sotyktu (deucravacitinib) is only available as a brand-name medication.
Summary for PDE-4 inhibitor
Prescription only
Otezla (apremilast) is a tablet that's taken by mouth. It's used to treat plaque psoriasis, psoriatic arthritis, and mouth sores from Behçet’s disease. This medication belongs to the drug class called phosphodiesterase-4 (PDE-4) inhibitors. You usually start Otezla (apremilast) at a low dose. Then, the dose is slowly raised over 5 days to lower the risk of side effects like nausea and diarrhea. This medication is available as a brand-name medication. Generic versions of apremilast likely won't be available until at least 2028.